Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice

Rheumatology International

Volumn 32, Issue 3, 2012, Pages 633-638

  He, Chunyan ^b   Lu, Xuehong ^a   Yan, Zhaowei ^a   Wu, Man ^a   Liu, Shujun ^a   Yu, Yongli ^b   Luo, Ping ^a  

^a JILIN UNIVERSITY   (China)

^b Basic Medical College   (China)

Author keywords

Leflunomide; Lupus nephritis; Treatment

Indexed keywords

AUTOANTIBODY; LEFLUNOMIDE; TOLL LIKE RECEPTOR 9; IMMUNOSUPPRESSIVE AGENT; ISOXAZOLE DERIVATIVE; TLR9 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; CELL PROLIFERATION; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; FEMALE; IMMUNE COMPLEX DEPOSITION; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN CELL; THERAPY EFFECT; ANIMAL; ANTIGEN ANTIBODY COMPLEX; BAGG ALBINO MOUSE; C57BL MOUSE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; INNATE IMMUNITY; KIDNEY; LONGEVITY; METABOLISM; PATHOLOGY; SPLEEN;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; ASCITES; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; GRAFT VS HOST DISEASE; IMMUNITY, INNATE; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; KIDNEY; LONGEVITY; LUPUS NEPHRITIS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SIGNAL TRANSDUCTION; SPLEEN; TOLL-LIKE RECEPTOR 9;

EID: 84863325859     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-010-1630-z     Document Type: Article

References (30)

1. Aurelia L, Philippe C, Isabelle A et al (2006) Role of TLR9 in anti-nucleosome and Anti-DNA antibody production in lpr mutation-induced murine lupus. J Immunol 177:1349-1354
2. Nagy G, Koncz A, Perl A (2005) T- and B-cell abnormalities in systemic lupus erythematosus. Crit Rev Immunol 25(2):123-140 (Pubitemid 40910585)
3. Hahn BH, Ebling F, Singh RR et al (2005) Cellular and molecular mechanisms of regulation of autoantibody production in lupus. Ann N Y Acad Sci 1051:433-441 (Pubitemid 41362773)
4. Christensen SR, Kashgarian M, Alexopoulou L et al (2005) Tolllike receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 202:321-331 (Pubitemid 41043827)
5. Nakano S, Morimoto S, Suzuki J et al (2008) Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology 47:145-149 (Pubitemid 351168222)
6. Laan RF, van Riel PL, van de Putte LB (2001) Leflunomide and methotrexate. Curr Opin Rheumatol 13(3):159-163 (Pubitemid 32430065)
7. Vidic-Dankovic B, Kosec D, Damjanovic M et al (1995) Leflunomide prevents the development of experimentally induced myasthenia gravis. Int J Immunopharmacol 17:273-281
8. Bartlett RR, Anagnostopulos H, Zielinski T et al (1993) Effects of leflumomide on immune responses and models of inflammation. Springer Semin Immunopathol 14:381-394 (Pubitemid 23145077)
9. Thomas K, Klaus T, Hans-Peter H, Stefan J (2001) Suppression of experimental autoimmune neuritis by leflunomide. Brain 124:1791-1802
10. Wang HY, Cui TG, Hou FF et al (2008) Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus 17(7):638-644
11. Zhang FS, Nie YK, Jin XM et al (2009) The efficacy and safety of lefunomide therapy in lupus nephritis by repeat kidney biopsy. Rheumatol Int 29(11):1331-1335
12. Tam LS, Li EK, Wong CK et al (2004) Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 13(8):601-604 (Pubitemid 39145490)
13. Wernick RM, Smith DL, Houghton DC et al (1993) Reliability of histologic scoring for lupus nephritis: a community-based evaluation. Ann Intern Med 119:805-811 (Pubitemid 24012646)
14. Trouw LA, Seelen MA, Duijs JM et al (2003) Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies. Clin Exp Immunol 132:32-39 (Pubitemid 36422600)
15. Van de Loosdrecht AA, Beelen RH, Ossenkoppele GJ et al (1994) A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods 174:311-320
16. Popovich S, Bartletr RR (1987) The use of the murine chronic graft versus host (CGVH) disease, a model for systemic lupus erythematosus (SLE) for drug discovery. Agents Actions 21:284
17. Bruijn JA, Van Elven EH, Hogendorn PCW et al (1988) Murine chronic graft versus host disease as a model for lupus nephritis. Am J Pathol 130:639
18. Rolink AG, Radaszkiewicz T, Melchers F (1987) The autoantigen binding B cell repertoires of normal and of chronically graft versus host diseased mice. J Exp Med 165:1675
19. Vidic-Dankovic B, Kosec D, Damjanovic M et al (1995) Leflunomide prevents thedevelopment of experimentally induced myasthenia gravis. Int J Immunopharmacol 17(4):273-281
20. Means TK, Latz E, Hayashi F et al (2005) Human lupus autoantibody- DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 115:407-417 (Pubitemid 40385482)
21. Rifkin IR, Leadbetter EA, Busconi L et al (2005) Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 205:27-42 (Pubitemid 40460491)
22. Anders HJ, Banas B, Schlondorff D (2004) Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 15:854-867 (Pubitemid 38375304)
23. Imai H, Hamai K, Komatsuda A et al (1997) IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis. Kidney Int 51:270-276 (Pubitemid 27064546)
24. Grootscholten C, van Bruggen MC, van der Pijl JW et al (2003) Deposition of nucleosomal antigens (histones and DNA) in the epidermal basement membrane in human lupus nephritis. Arthritis Rheum 48:1355-1362 (Pubitemid 36554534)
25. Bootsma H, Spronk PE, Ter Borg EJ et al (1997) The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus: a prospective longterm observation. Ann Rheum Dis 56:661-666 (Pubitemid 28007923)
26. Clough JD, Valenzuela R (1980) Relationship of renal histopathology in SLE nephritis to immunoglobulin class of anti-DNA. Am J Med 68:80-85 (Pubitemid 10207622)
27. Taki S, Hirose S, Kinoshita K et al (1992) Somatically mutated IgG anti-DNA antibody clonally related to germ-line encoded IgM anti-DNA antibody. Eur J Immunol 22:987-992
28. Pisetsky DS, Jelinek DF, McAnally LM et al (1990) In vitro autoantibody production by normal adult and cord blood B cells. J Clin Invest 85:899-903 (Pubitemid 20087494)
29. Witte T, Hartung K, Sachse C et al (1998) IgM anti-dsDNA antibodies in systemic lupus erythematosus: negative association with nephritis. Rheumatol Int 18:85-91 (Pubitemid 28505328)
30. Forger F, Matthias T, Oppermann M et al (2004) Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of antidsDNA antibodies as a prognostic marker for lupus nephritis. Lupus 13:36-44 (Pubitemid 38129349)